The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease

Tohoku Journal of Experimental Medicine

Volumn 227, Issue 4, 2012, Pages 253-262

  Cao, Chuang Yu ^a   Li, Yu Yuan ^a   Zhou, Yong Jian ^a   Nie, Yu Qiang ^a   Wan, Yu Jui Yvonne ^b  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Gene; Insulin resistance; Non alcoholic fatty liver disease; Peroxisome proliferator activated receptor ; Polymorphism

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PPAR GAMMA GENE; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; DEMOGRAPHY; FATTY LIVER; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84864441925     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.227.253     Document Type: Article

References (55)

1. Altshuler, D., Hirschhorn, J.N., Klannemark, M., Lindgren, C.M., Vohl, M.C., Nemesh, J., Lane, C.R., Schaffner, S.F., Bolk, S., Brewer, C., Tuomi, T., Gaudet, D., Hudson, T.J., Daly, M., Groop, L. & Lander, E.S. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet., 26, 76-80.
2. Amarapurkar, D.N., Hashimoto, E., Lesmana, L.A., Sollano, J.D., Chen, P.J. & Goh, K.L. (2007) How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J. Gastroenterol. Hepatol., 22, 788-793.
3. American Gastroenterological Association. (2002) American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology, 123, 1702-1704.
4. Argo, C.K. & Caldwell, S.H. (2009) Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis., 13, 511-531.
5. Badii, R., Bener, A., Zirie, M., Al-Rikabi, A., Simsek, M., Al-Hamaq, A.O., Ghoussaini, M., Froguel, P. & Wareham, N.J. (2008) Lack of association between the Pro12Ala polymorphism of the PPAR-gamma 2 gene and type 2 diabetes mellitus in the Qatari consanguineous population. Acta. Diabetol., 45, 15-21.
6. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
7. Blackburn, G.L. (2010) From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor gamma modulators. Am. J. Clin. Nutr., 91, 251S-253S.
8. Caldwell, S.H., Argo, C.K. & Al-Osaimi, A.M. (2006) Therapy of NAFLD: insulin sensitizing agents. J. Clin. Gastroenterol., 40 (Suppl 1), S61-66.
9. Daly, A.K., Ballestri, S., Carulli, L., Loria, P. & Day, C.P. (2011) Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol., 5, 253-263.
10. Day, C.P. (2006) Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int., 26, 1021-1028.
11. Deeb, S.S., Fajas, L., Nemoto, M., Pihlajamäki, J., Mykkänen, L., Kuusisto, J., Laakso, M., Fujimoto, W. & Auwerx, J. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet., 20, 284-287.
12. Dongiovanni, P., Rametta, R., Fracanzani, A.L., Benedan, L., Borroni, V., Maggioni, P., Maggioni, M., Fargion, S. & Valenti, L. (2010) Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with nonalcoholic fatty liver disease: a case control study. BMC Gastroenterol., 10, 102.
13. Fajas, L., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre, A.M., Saladin, R., Najib, J., Laville, M., Fruchart, J.C., Deeb, S., Vidal-Puig, A., Flier, J., Briggs, M.R., Staels, B., Vidal, H. & Auwerx, J. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 272, 18779-18789.
14. Fan, J.G., Zhu, J., Li, X.J., Chen, L., Lu, Y.S., Li, L., Dai, F., Li, F. & Chen, S.Y. (2005) Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol., 20, 1825-1832.
15. Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. (2006) Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases. Zhonghua Gan Zang Bing Za Zhi, 14, 161-163.
16. Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P., Leal, S.M., Pasternak, S., Wheeler, D.A., Willis, T.D., Yu, F., Yang, H., et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851-861.
17. Gupta, A.C., Chaudhory, A.K., Sukriti Pande, C., Sakhuja, P., Singh, Y., Basir, S.F. & Sarin, S.K. (2010) Peroxisome proliferators-activated receptor gamma2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol. Int., 5, 575-580.
18. Gurnell, M. (2005) Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies. Best Pract. Res. Clin. Endocrinol. Metab., 19, 501-523.
19. Haiman, C.A. & Stram, D.O. (2008) Utilizing HapMap and tagging SNPs. Methods Mol. Med., 141, 37-54.
20. Heude, B., Pelloux, V., Forhan, A., Bedel, J.F., Lacorte, J.M., Clement, K. & Charles, M.A. (2011) Association of the Pro12Ala and C1431T variants of PPARgamma and their haplotypes with susceptibility to gestational diabetes. J. Clin. Endocrinol. Metab., 96, E1656-1660.
21. International HapMap Consortium. (2003) The International HapMap Project. Nature, 426, 789-796.
22. International HapMap Consortium. (2005) A haplotype map of the human genome. Nature, 437, 1299-1320.
23. Jaziri, R., Lobbens, S., Aubert, R., Péan, F., Lahmidi, S., Vaxillaire, M., Porchay, I., Bellili, N., Tichet, J., Balkau, B., Froguel, P., Marre, M. & Fumeron, F. (2006) The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes, 55, 1157-1162.
24. Kallwitz, E.R., McLachlan, A. & Cotler, S.J. (2008) Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol., 14, 22-28.
25. Kim, H.K., Park, J.Y., Lee, K.U., Lee, G.E., Jeon, S.H., Kim, J.H. & Kim, C.H. (2009) Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am. J. Med. Sci., 337, 98-102.
26. Kotronen, A., Yki-Järvinen, H., Aminoff, A., Bergholm, R., Pietiläinen, K.H., Westerbacka, J., Talmud, P.J., Humphries, S.E., Hamsten, A., Isomaa, B., Groop, L., Orho-Melander, M., Ehrenborg, E. & Fisher, R.M. (2009) Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol., 160, 593-602.
27. Liu, D.X., Hua, Q., Liu, L.S. & Guo, J.C. (2008) Association of peroxisome proliferator-activated receptorgamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ. J., 72, 551-557.
28. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
29. Meirhaeghe, A. & Amouyel, P. (2004) Impact of genetic variation of PPARgamma in humans. Mol. Genet. Metab., 83, 93-102.
30. Meirhaeghe, A., Cottel, D., Amouyel, P. & Dallongeville, J. (2005) Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol. Genet. Metab., 86, 293-299.
31. Meirhaeghe, A., Fajas, L., Gouilleux, F., Cottel, D., Helbecque, N., Auwerx, J. & Amouyel, P. (2003) A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler. Thromb. Vasc. Biol., 23, 289-294.
32. Meirhaeghe, A., Tanck, M.W., Fajas, L., Janot, C., Helbecque, N., Cottel, D., Auwerx, J., Amouyel, P. & Dallongeville, J. (2005) Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol. Genet. Metab., 85, 140-148.
33. Mendez-Sanchez, N., Arrese, M., Zamora-Valdes, D. & Uribe, M. (2007) Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int., 27, 423-433.
34. Mishra, P. & Younossi, Z.M. (2007) Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am. J. Gastroenterol., 102, 2716-2717.
35. Osterreicher, C.H. & Brenner, D.A. (2007) The genetics of nonalcoholic fatty liver disease. Ann. Hepatol., 6, 83-88.
36. Ranjith, N., Pegoraro, R.J., Naidoo, D.P., Shanmugam, R. & Rom, L. (2008) Genetic variants associated with insulin resistance and metabolic syndrome in young Asian Indians with myocardial infarction. Metab. Syndr. Relat. Disord., 6, 209-214.
37. Rey, J.W., Noetel, A., Hardt, A., Canbay, A., Alakus, H., Zur Hausen, A., Dienes, H.P., Drebber, U. & Odenthal, M. (2010) Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 in patients with fatty liver diseases. World J. Gastroenterol., 16, 5830-5837.
38. Ryysy, L., Häkkinen, A.M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J. & Yki-Järvinen, H. (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes, 49, 749-758.
39. Semple, R.K., Chatterjee, V.K. & O'Rahilly, S. (2006) PPAR gamma and human metabolic disease. J. Clin. Invest., 116, 581-589.
40. Seppälä-Lindroos, A., Vehkavaara, S., Häkkinen, A.M., Goto, T., Westerbacka, J., Sovijärvi, A., Halavaara, J. & Yki-Järvinen, H. (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab., 87, 3023-3028.
41. Shannon, A., Alkhouri, N., Carter-Kent, C., Monti, L., Devito, R., Lopez, R., Feldstein, A.E. & Nobili, V. (2011) Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J. Pediatr. Gastroenterol. Nutr., 53, 190-195.
42. Shi, Y.Y. & He, L. (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res., 15, 97-98.
43. Tönjes, A. & Stumvoll, M. (2007) The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr. Opin. Clin. Nutr. Metab. Care., 10, 410-414.
44. Wan, J., Xiong, S., Chao, S., Xiao, J., Ma, Y., Wang, J. & Roy, S. (2010) PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc. Diabetol., 9, 13.
45. Wei, Q., Jacobs, D.R. Jr., Schreiner, P.J., Siscovick, D.S., Steffes, M.W. & Fornage, M. (2006) Patterns of association between PPARgamma genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA Study. J. Mol. Med (Berl)., 84, 955-965.
46. Wilfred de Alwis, N.M. & Day, C.P. (2007) Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis., 27, 44-54.
47. Williams, R. (2006) Global challenges in liver disease. Hepatology, 44, 521-526.
48. Yajima, Y., Ohta, K., Narui, T., Abe, R., Suzuki, H. & Ohtsuki, M. (1983) Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J. Exp. Med., 139, 43-50.
49. Yang, H., Li, Y.Y., Nie, Y.Q., Sha, W.H., Du, Y.L., Lai, X.B. & Zhou, Y.J. (2008) Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of nonalcoholic fatty liver disease in Chinese people. Liver Int., 28, 385-392.
50. Yang, L.L., Hua, Q., Liu, R.K. & Yang, Z. (2009) Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Arch. Med. Res., 40, 89-96.
51. Yang, Z., Wen, J., Li, Q., Tao, X., Ye, Z., He, M., Zhang, W., Huang, Y., Chen, L., Ling, C., Qu, S. & Hu, R. (2012) PPARG gene Pro12Ala variant contributes to the development of nonalcoholic fatty liver in middle-aged and older Chinese population. Mol. Cell. Endocrinol., 348, 255-259.
52. Ye, Q. & Lv, Z.S. (2007) [A study of the association between PPARr2 gene Pro12Ala polymorphism and NAFLD]. Zhonghua Gan Zang Bing Za Zhi, 15, 228-229.
53. Zhou, Y.J., Li, Y.Y., Nie, Y.Q., Ma, J.X., Lu, L.G., Shi, S.L., Chen, M.H. & Hu, P.J. (2007) Prevalence of fatty liver disease and its risk factors in the population of South China. World J. Gastroenterol., 13, 6419-6424.
54. Zhou, Y.J., Li, Y.Y., Nie, Y.Q., Yang, H., Zhan, Q., Huang, J., Shi, S.L., Lai, X.B. & Huang, H.L. (2010) Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J. Gastroenterol. Hepatol., 25, 772-777.
55. Zimmet, P., Alberti, K.G., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., Wong, G., Bennett, P., Shaw, J. & Caprio, S. (2007) The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr. Diabetes, 8, 299-306.